stabl revenu growth oper margin expans
support healthi earn growth agil
updat forecast estim aug
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research aug
estim aug
price data aug
rate updat aug
currenc amount express
valuat growth profit
methodolog valu compani
spun hewlett-packard agil evolv
seri transact lead healthcar firm market
share leader mani core product categori especi ga
chromatographi mass spectrometri agil global
measur giant use technolog expertis global
reach serv broad base scienc engin custom
spin electron segment novemb
name agil focus sole
life scienc diagnost chemic analysi market
agil leverag competit edg electron
measur market emerg major player life
scienc market spin-off electron unit allow
agil focu chemic analysi life scienc market
present better growth opportun enhanc
compani moat higher barrier entri switch
field despit near-term challeng
constrain academ research budget weak oil ga
market agil continu benefit higher growth
among biopharma research appli industri market
also think manag priorit build diagnost
busi acquisit dako compani
smaller market share less expertis potenti
faster-grow larger clinic market opportun
agil possess larg global market distribut
infrastructur leav firm well-equip handl
competit enhanc profit oper margin
method improv sinc see gain ahead
recent effici cost-sav effort -- streamlin
suppli chain exit unprofit nmr busi enhanc
procur consolid facil outsourc noncrit
task -- boost profit make agil less suscept
swing demand compani decad ago agil
direct presenc emerg market also help solidifi custom
relationship help enhanc demand
compani product faster-growth region
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
origin spun hewlett-packard agil evolv
broad base custom within three oper segment life scienc
appli equip sale cross lab includ
consum servic diagnost genom
unit state europ account revenu
respect china japan account major remain
sale agil headquart california
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
agil continu benefit biopharma
narrow-moat agil slightli rais year-end outlook
result
incorpor organ growth oper margin
basi point last year may
slightli increas fair valu estim modestli
boost year-end bottom-lin forecast even though
revenu adjust ep forecast billion
respect close manag current
expect billion midpoint
year manag guidanc impli organ growth
roughli fiscal fourth quarter look
conserv us despit grow concern
chines tariff depress demand rais input cost
larg see agil revenu growth margin
expans goal attain thank new product
initi includ manufactur expans nucleic
acid solut compani abil adjust supply-
chain sourc china
agil biopharma chemic energi market
remain key near-term growth driver weve seen
peer biopharma segment -- report anoth quarter
stabl organ growth agil -- continu
benefit healthi underli demand biolog
small-molecul drug research addit turnaround
chemic energi market wit past
quarter persist organ growth
quarter help strong semiconductor custom demand
similar last quarter segment continu off-set
modest weak academ environment food
segment note last quarter restructur
chines regulatori agenc hit food-rel sale
particularli hard anoth quarter sale declin
custom segment regardless still view mani
issu transitori current stronger
segment support mid-single-digit growth firm
valuat growth profit aug
rais fair valu estim agil per
share slightli rais near-term revenu
margin forecast along cash flow realiz sinc
price/adjust earn multipl approxim
model incorpor nearli annual growth
next five year think adjust earn grow
close time frame thank oper
leverag effici effort share repurchas
annual growth result mid-single-digit
growth agil life scienc appli divis
biopharma food industri growth along recent
recoveri energi market custom base help
off-set weaker growth academ govern
segment expect modest recoveri agil sale
improv market condit continu slowli eas
custom budget constraint especi academ
research market agil growth appli
diagnost market remain rel strong market
share gain new product launch rise
contribut emerg market also help boost
expect profit continu improv year
ahead product mix oper leverag cost-sav
initi synergi acquisit agil also
exit less profit busi nmr mri
busi acquir varian deal compani
improv economi scale life scienc
diagnost market also eventu drive
consider portion consolid margin expans
assum modest margin expans life scienc
diagnost segment lead adjust oper margin
near model assumpt culmin
five-year averag return capit high teen
estim agil cost capit approxim
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
busi segment hinder growth profit
next sever year adjust oper
margin remain near expans effort stall due
strong compet platform peer slowdown
emerg market continu budgetari constraint
auster measur price pressur bear-cas fair
valu estim per share return capit
averag high teen
high custom switch cost moder barrier
entri competitor primari ingredi agil
narrow econom moat opinion extens
portfolio intang asset far-reach global
infrastructur also critic support compani
agil benefit much peer
recur consum sale compani nonetheless
enjoy long product life cycl typic five year
high custom retent rate persist decad
agil cater highli skill engin scientist
face steep learn curv sizabl up-front invest
util special highli sensit equip
market scientist often remain loyal supplier
ensur sampl protect standard
valid requir scientif research regulatori
reinforc high switch cost brand
instrument reagent market tend
incorpor high level technolog complex
also keep barrier entri somewhat high opinion
addit challeng manufactur reliabl
complex instrument think necessari servic
compon
consult repair present hurdl new entrant
market
award agil medium uncertainti rate thank
rel high barrier entri moder switch
cost mostli stabl product evolut
chromatographi diagnost instrument market
bull-cas scenario assum new product
launch help compani continu gain market share
agil custom maintain healthi spend
level also forecast stronger growth within asian
emerg market assum firm abl capit
strong demand trend key end segment exampl
need food safeti scenario project
compound annual growth near overal revenu
exceed billion strong price cost
control effort lead adjust oper margin
bull-cas fair valu estim per
bear case competit price pressur across
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
establish reput brand supplement exist
offer keep pace technolog advanc
agil consist alloc larg portion resourc
toward research develop sale
acquisit dako exampl brought signific
capabl scale within anatom patholog
market boost agil percentag recur
think agil moat support stabl posit
firm comfort oligopoli includ consist
competitor shimadzu thermo fisher
agil roughli market
share life scienc diagnost chemic analysi
divis estim howev within larg market
chemic energi
environment food segment thank larg part
compani domin within ga chromatographi
market dako acquisit agil roughli
market share anatom patholog market
tissue-bas cancer diagnost make major player
roch
agil stabl moat trend view compet
rel stabl market think risk disrupt
technolog low particularli matur chemic
analysi market agil on-going transit
clinic diagnost appli market pose new
concentr
potenti lower brand loyalti pit power foe
nimbl entrant disrupt technolog like genom
sequenc agil may difficulti translat
histor advantag clinic market regardless
think agil familiar competit dynam
within clinic diagnost market includ workflow
matter addit agil proven histori
industri accret
adapt new
acquisit
instrument autom
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
oagil well-establish leader mani core
familiar agil
instrument servic make market share
gain new entrant difficult
oa signific portion agil busi
depend research compos larg academ
govern institut like face
continu budget constraint near term
oagil spin-off electron measur
segment free resourc focu build
compani life scienc diagnost
chemic analysi oper -- higher-growth
differenti industri
oth acquisit dako enhanc agil
access higher-growth larger clinic
diagnost market boost compani
oagil must continu innov stay
forefront technolog advanc particularli
compet even larger compani
oacquisit divest central
compon agil strategi place high
demand manag abil execut market
expans integr goal
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
agil retain strong financi posit view
end fiscal year octob compani
billion cash balanc exceed nearli billion total debt
compani gross debt/ebitda remain around
comfort ebitda interest expens coverag ratio
greater manag continu return
signific capit sharehold dividend
share repurchas although larg acquisit
common agil manag like continu
util portion free cash flow smaller deal
award agil medium uncertainti rate thank
rel high barrier entri moder switch
cost mostli stabl product evolut
chromatographi diagnost instrument market agil
larg depend capit equip sale
volatil subject macroeconom condit
compon agil suscept capital-spend
cycl roic could risk event prolong
downturn although focus reduc relianc
agil still gener level high-margin
consum servic sale wide- narrow-moat
rival includ thermo fisher
agil also oper competit environ
establish competitor new entrant introduc better
product develop stronger relationship custom
compani may lose market share well abil
extract price increas moreov compani compet
mani smaller more-focus rival invest
signific resourc segment requir
maintain technolog edg exampl agil
current particip equip side
genom sequenc market could pose risk
road technolog potenti displac
current research clinic method regardless agil
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
larg chromatographi mass spectrometri busi
seem larg immun disrupt technolog
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
new york mellon corp
fidel manag research compani
share
fund
share
fund
assign compani standard mark stewardship
term capit alloc think manag wise
use acquisit divestitur keysight
technolog spin-off improv asset product
agil may aggress consolid
peer thermo fisher think
manag disciplin help uphold consist
attract return capit also believ manag
display nice track record use deal build
capabl within new market acquisit
dako exampl come steep price tag think
manag make appropri stride improv
busi asset util purchas step
stone enter higher-growth clinic diagnost arena
spin-off keysight mike mcmullen previous
presid chemic analysi segment sinc
replac william sullivan ceo agil earli
mcmullen long histori compani origin
hewlett-packard date back william sullivan
agil veteran compani sinc
spin-off hewlett-packard previous
agil ceo sinc full retir octob
sullivan remain advisori role
mcmullen transit leadership didier hirsch also
hewlett-packard veteran like mcmullen retir cfo
octob replac robert mcmahon
mcmahon cfo sinc mcmullen
also possess one seat agil board
jame cullen chairman board
although board switch measur
execut compens oper margin adjust
ep instead return capit think manag
compens reason option issuanc
excess
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
agil continu benefit biopharma
narrow-moat agil slightli rais year-end outlook
result
incorpor organ growth oper margin
basi point last year may
slightli increas fair valu estim modestli
boost year-end bottom-lin forecast even though
revenu adjust ep forecast billion
respect close manag current
expect billion midpoint
year manag guidanc impli organ growth
roughli fiscal fourth quarter look
conserv us despit grow concern
chines tariff depress demand rais input cost
larg see agil revenu growth margin
expans goal attain thank new product
initi includ manufactur expans nucleic
acid solut compani abil adjust supply-
chain sourc china
agil biopharma chemic energi market
remain key near-term growth driver weve seen
peer biopharma segment -- report anoth quarter
stabl organ growth agil -- continu
benefit healthi underli demand biolog
small-molecul drug research addit turnaround
chemic energi market wit past
quarter persist organ growth
quarter help strong semiconductor custom demand
similar last quarter segment continu off-set
modest weak academ environment food
segment note last quarter restructur
chines regulatori agenc hit food-rel sale
particularli hard anoth quarter sale declin
custom segment regardless still view mani
issu transitori current stronger
segment support mid-single-digit growth firm
narrow-moat agil face setback second
plan slightli lower full-year forecast agil
follow compani fiscal second-quart result
thank part currenc effect anticip leav
fair valu estim narrow moat rate
anticip result due icp-m shipment delay
food safeti agenc reorgan china
depress order countri howev on-going strong
base led manag keep full-year outlook
unchang believ year-end goal achiev
still view share overvalu
agil strong first-quart result due part time
lunar new year celebr china compani
face number challeng across sever market
segment govern safeti agenc reorgan
china led organ declin food segment sale
quarter manag anticip rebound
potenti take remaind year chemic
energi segment sale also bit weaker
anticip price oil climb manag
note custom apprehens possibl relat
recent tariff propos regardless expect recoveri
energi market remain tailwind agil academ
govern sale also post sluggish organ
growth diagnost divis post growth
weak stem pain manag area
regardless still think manag organ
growth target year look achiev long-term
margin expans goal still track
adjust oper margin fell basi point
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
last year neg currenc effect mask otherwis
profit although recent
acquisit subtract underli profit
improv still gener view manag
capit alloc decis benefici compani
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end octob
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end octob
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
